NCT05059509View on ClinicalTrials.gov

Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 6, 2020

Primary Completion Date

May 10, 2021

Study Completion Date

March 31, 2022

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

FB825

FB825, 5mg/kg, by 1 hour IV infusion on Day 1

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Oneness Biotech Co., Ltd.

INDUSTRY